新辅助放化疗后食管鳞状细胞癌的改良整块食管切除术
该研究分析了2012至2021年间接受新辅助放化疗后手术的食管鳞状细胞癌患者238例,比较改良整块食管切除术(mEBE)与常规食管切除术(CE)的围手术期结局和生存率。结果显示mEBE手术时间更长、清扫淋巴结总数更多、并发症更少、吻合口漏更少,住院时间相似;在非ypT0N0期患者中mEBE的3年总生存率和无病生存率均优于CE,而ypT0N0期患者两组无差异。
要点
- mEBE与CE相比,手术时间更长、清扫淋巴结总数更多、并发症更少、吻合口漏更少,住院时间相似。
- ypT0N0期患者中mEBE与CE的总生存率无差异。
- 非ypT0N0期患者中mEBE的3年总生存率为58.5%,CE为28.5%(P < .001)。
核心结论
- mEBE术后生存率显著优于CE。
- mEBE未增加术后住院时间和并发症发生率。
研究设计与样本
- 分析2012年至2021年间接受新辅助放化疗后切除的食管鳞状细胞癌患者数据。
- 共纳入238例患者,比较mEBE与CE的围手术期结局和生存率。
- mEBE包括全纵隔淋巴结清扫和切除所有食管周围含淋巴结组织。
主要发现
- 与CE相比,mEBE手术时间更长、清扫淋巴结总数更高、并发症更少、吻合口漏更少;两组住院时间相似。
- ypT0N0期患者中mEBE组与CE组总生存率无差异。
- 非ypT0N0期患者中mEBE组与CE组的3年总生存率分别为58.5%和28.5%(P < .001)。
- 无病生存分析中,ypT0N0期患者两组无差异;非ypT0N0期患者mEBE组无病生存率显著优于CE组(49.7% vs 27.2%;P = .017)。
关键数值与推荐
- 非ypT0N0期患者mEBE组3年总生存率58.5% vs CE组28.5%(P < .001)。
- 非ypT0N0期患者mEBE组无病生存率49.7% vs CE组27.2%(P = .017)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal type of esophagectomy and extent of lymphadenectomy for patients after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma remain controversial. We hypothesized that a more radical resection is associated with better survival. METHODS: Data of patients who received nCRT followed by resection for esophageal squamous cell carcinoma between 2012 and 2021 were analyzed. Modified en bloc esophagectomy (mEBE) involves total mediastinal lymphadenectomy and resection of all periesophageal node-bearing tissues. Perioperative outcomes and survival rates of mEBE were compared with those of conventional esophagectomy (CE). RESULTS: A total of 238 patients were included. Compared with CE, mEBE was associated with a longer operative time, higher total number of resected lymph nodes, fewer complications, and less anastomotic leakage; length of stay was similar between the 2 groups. There was no difference in overall survival rates between patients with ypT0 N0 stage in the mEBE and CE groups; however, in patients with non-ypT0 N0 stage in the mEBE and CE groups, the 3-year overall survival rates were 58.5% and 28.5%, respectively (P < .001). On disease-free survival analysis, no difference was observed in patients with ypT0 N0 stage, whereas patients with non-ypT0 N0 stage after nCRT had significantly better disease-free survival after mEBE compared with CE (49.7% vs 27.2%; P = .017). CONCLUSIONS: Survival after mEBE was significantly better than that after CE. The mEBE did not increase postoperative hospital stay and complication rates.
引用
- Hsu PK, Chien LI, Chuang LC, et al. Modified En Bloc Esophagectomy for Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy. Ann Thorac Surg. 2023. PMID: 36669675. doi:10.1016/j.athoracsur.2023.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。